UK Lung Cancer Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
UK · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$990.8 MnPlaceholder estimate
Estimate 2025$1.07 Bn2.7% of the global market
Projected 2034$2.06 Bn 93.3%Adds $995.0 Mn over 9 forecast years
CAGR 2025–20347.6%Faster than 59% of 180 Pharmaceuticals markets here
290 in the UKSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The UK Lung Cancer Therapeutics Market Analysis Executive Summary
Lung cancer therapeutics include targeted drugs, immunotherapy, chemotherapy and antibody-drug conjugates for small-cell and non-small cell lung cancer.
Key segments of the lung Cancer Therapeutics market include drug class (Targeted Therapy, Immunotherapy and Chemotherapy) and type (Non-Small Cell Lung Cancer and Small Cell Lung Cancer).
UK Lung Cancer Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
UK Lung Cancer Therapeutics Market Dynamics
Market Growth Drivers
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the lung Cancer Therapeutics market. Faster approvals and new combinations are improving survival.
Opportunity
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the lung Cancer Therapeutics market.
Market Restraints
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the lung Cancer Therapeutics market, especially in low- and middle-income countries.
Competitive Landscape for Lung Cancer Therapeutics Market in UK
The lung Cancer Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Lung Cancer Therapeutics Market in UK
Lung Cancer Therapeutics in the UK: rules, payment and research
The Medicines and Healthcare products Regulatory Agency (MHRA) licenses medicines in the UK.[1] The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund.[2] ClinicalTrials.gov lists 290 studies on Lung Cancer Therapeutics that are recruiting, active or about to start in the UK.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for lung Cancer Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in UK.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug Class
4.2 By Type
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Merck & Co.
7.2 AstraZeneca
7.3 Roche
7.4 Bristol Myers Squibb
7.5 Amgen
7.6 Johnson & Johnson
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The lung Cancer Therapeutics market can be segmented based on various criteria, including drug class, type and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Lung Cancer Therapeutics right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Lung Cancer Therapeutics in context
The UK compared
Health spending per person: 5,860 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 6 countries we cover in Europe.[1]
Doctors: 3.30 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 5th highest of the 6 countries we cover in Europe.[2]
People aged 65 and over: 19.7% of people (2025). World: 10.4% of people (2025). 5th highest of the 6 countries we cover in Europe.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.
How big is the Lung Cancer Therapeutics market in the UK?
Placeholder estimate: about $1.07 Bn in 2025, rising to about $2.06 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Lung Cancer Therapeutics market in the UK growing?
Placeholder estimate: about 7.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Lung Cancer Therapeutics market report cover?
The report splits the market by drug class (Targeted Therapy, Immunotherapy, Chemotherapy, Antibody-Drug Conjugates), type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Lung Cancer Therapeutics market?
Key players include Merck & Co., Inc., AstraZeneca, Roche, Bristol-Myers Squibb, Amgen Inc. and Johnson & Johnson.
What is driving the Lung Cancer Therapeutics market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the lung Cancer Therapeutics market. Faster approvals and new combinations are improving survival.
The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund. Source: National Institute for Health and Care Excellence. Checked 14 Nov 2026.
How many clinical trials on Lung Cancer Therapeutics are running in the UK?
290 studies are recruiting, active or about to start in the UK, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
How much research is published on Lung Cancer Therapeutics?
PubMed lists 50 papers on Lung Cancer Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.